جميع الدراسات
التوظيفالمرحلة 1، المرحلة 2تدخلي

A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)

This clinical trial, called CARDINAL, is looking into a new drug, TERN-701, for adults who have a type of blood cancer called Chronic Myeloid Leukemia (CML) in the chronic phase. These are people whose CML hasn't responded as expected to previous treatments. The study has two main parts. The first part focuses on finding the safest and most effective dose of TERN-701. The second part then uses these doses to see how well the medicine works and compare it in more people. There's also a smaller part for those with specific genetic changes in their CML. TERN-701 is designed to specifically target the cause of CML. Researchers want to understand if it's a good and safe option for patients who need new treatment choices.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 1، المرحلة 2
الراعي
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
الهدف من التسجيل
330
ابدأ
26 مارس 2024
التاريخ المتوقع للانتهاء
31 May 2030

ما هو موضوع هذه الدراسة؟

This study is about a new treatment called TERN-701 for a type of blood cancer known as Chronic Myeloid Leukemia, or CML. CML is a long-lasting condition where too many white blood cells are made. Regularly, people with CML are treated with other medicines, but sometimes these don't work as well as hoped, or cause side effects that are too difficult to manage. This study offers a new option for these patients.

TERN-701 works by targeting a specific protein (called BCR-ABL1) that is responsible for CML. Researchers want to find out if this new medicine is safe, what the right dose is, how the body handles it, and how effective it is at treating CML. This is a "Phase 1/2" study, meaning it's still in the earlier stages of testing new drugs in people.

The study is divided into different stages. Initially, a small group of patients will try increasing doses of TERN-701 to find the safest and most effective amount (this is called Part 1, or Dose Escalation). Once the researchers have a better idea of the right doses, more patients will join (Part 2, or Dose Expansion) to further check how well the treatment works and its safety. There's also a specific group (Part 2m) for patients whose CML has certain genetic changes that might make it harder to treat.

النقاط الرئيسية

  • New medicine (TERN-701) for CML in chronic phase.
  • For those whose previous CML treatments haven't worked well.
  • Study checks safety, best dose, and effectiveness of TERN-701.
  • Involves taking daily medicine and regular clinic visits.
  • Participants will receive the active study drug, not a placebo.
  • يمكنك التوقف عن المشاركة في أي وقت.

من قد يكون مؤهلاً؟

To join this study, you need to be at least 18 years old and have a confirmed diagnosis of Chronic Myeloid Leukemia (CML) in its chronic phase. Importantly, your CML should have been treated before with at least one other CML medicine, but it hasn't responded well enough, or you've found the side effects too difficult. You'll also need to be generally well enough to take part, as assessed by the study doctors.

There are also some reasons why you wouldn't be able to join. For example, if you've recently had other cancer treatments in the last 7 days, or if you still have significant side effects from previous treatments. The study doctors will carefully check all your medical information to make sure this study is right for you.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. هل عمرك 18 سنة أو أكثر؟
  2. Do you have a diagnosis of Chronic Myeloid Leukemia (CML) in the chronic phase?
  3. Have you tried at least one other CML treatment that didn't work well or caused difficult side effects?
  4. Are you generally well enough for a clinical study?
  5. Have you avoided other cancer treatments in the last 7 days?
  6. Are any major side effects from previous treatments resolved or well-controlled?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you join this study, you will take TERN-701 as a once-daily medicine. This treatment will be given in cycles, with each cycle lasting 28 days. You'll continue taking the medicine every day over these cycles.

During the treatment, you will have several scheduled visits to the study centre. In the first cycle, you'll have visits on Day 1, Day 2, Day 8, Day 15, and Day 16. For Cycles 2 through 7, you'll visit on Day 1 of each cycle. After that, you'll visit on Day 1 of every third cycle. These visits are important so the study team can monitor your health, check how you're responding to the treatment, and manage any side effects. Approximately 180 people might join this study.

المخاطر والفوائد المحتملة

Taking part in this study means you'll receive a new potential treatment for your CML, which might work better for you if other treatments haven't. However, as with any new medicine, there could be side effects that are not yet fully known. The study team will closely monitor you for any problems. It's important to remember that joining a study is always your choice, and you are free to leave the study at any time, for any reason, without it affecting your usual medical care.

المواقع (54)

  • University of Alabama Medicine (UAB Medicine)
    الرمز البريدي المؤكد
    برمنغهام، الولايات المتحدة· التوظيف
  • لافتة مركز إم دي أندرسون للسرطان
    الرمز البريدي المؤكد
    جيلبرت، الولايات المتحدة· التوظيف
  • UC Irvine Health
    الرمز البريدي المؤكد
    أورانج، الولايات المتحدة· التوظيف
  • Rocky Mountain Cancer Centers, LLP
    الرمز البريدي المؤكد
    لون تري، الولايات المتحدة· التوظيف
  • Florida Cancer Specialists - South Region Research Office
    الرمز البريدي المؤكد
    فورت مايرز، الولايات المتحدة· لم يبدأ التوظيف بعد
  • Florida Cancer Affiliates - Ocala
    الرمز البريدي المؤكد
    أوكالا، الولايات المتحدة· التوظيف
  • Florida Cancer Specialists - North Region Research Office
    الرمز البريدي المؤكد
    سانت بطرسبرغ، الولايات المتحدة· لم يبدأ التوظيف بعد
  • Florida Cancer Specialists - East Region Research Office
    الرمز البريدي المؤكد
    West Palm Beach, United States· لم يبدأ التوظيف بعد
  • Georgia Cancer Center at Augusta University
    الرمز البريدي المؤكد
    أوغوستا، الولايات المتحدة· التوظيف
  • Memorial Sloan Kettering Cancer Center - Main Campus
    الرمز البريدي المؤكد
    نيويورك، الولايات المتحدة· التوظيف
  • Atrium Health Levine Cancer Institute
    الرمز البريدي المؤكد
    وينستون-سالم، الولايات المتحدة· التوظيف
  • Willamette Valley Cancer Institute and Research Center
    الرمز البريدي المؤكد
    يوجين، الولايات المتحدة· التوظيف

أسئلة شائعة

What is CML?

CML stands for Chronic Myeloid Leukemia, which is a type of cancer that affects the blood and bone marrow, causing the body to produce too many white blood cells.

What is TERN-701?

TERN-701 is a new medicine being tested. It's designed to specifically target the cause of CML, particularly in people whose current treatments haven't worked well.

Why are there different 'parts' to the study?

The study has different parts to safely find the best dose (Part 1) and then to test that dose in more people to see how effective it is and understand its safety further (Part 2 and Part 2m).

كم مرة سأحتاج لزيارة العيادة؟

You'll have more frequent visits at the beginning of the study, especially during the first cycle, and then less often as the treatment continues, typically once every three cycles after the seventh cycle.

Will I definitely receive the new drug?

Yes, everyone who joins this study will receive the active study medicine, TERN-701, at a specific dose.

كيفية معرفة المزيد

رقم مجاني

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "A Clinical Study of MK-4208/TERN-701 in Participants With Ch… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.